100 likes | 202 Views
Recommendation: Sell Stryker (SYK). Green & Gold Fund. Healthcare holdings. Abbott Labs (ABT) Stryker Corp (SYK) Healthcare Select ETF (XLV). Rationale for Sale. Earnings revisions by analysts and management Recent recalls / FDA limitations / potential litigation
E N D
Recommendation: Sell Stryker (SYK) Green & Gold Fund
Healthcare holdings • Abbott Labs (ABT) • Stryker Corp (SYK) • Healthcare Select ETF (XLV)
Rationale for Sale • Earnings revisions by analysts and management • Recent recalls / FDA limitations / potential litigation • Slower overseas adoption of products than anticipated • New CEO, no full time CFO • Better opportunities elsewhere • Healthcare indices have rallied this year, with only modest gains by SYK • Starting in 2013, the Affordable Care Act mandates a 2.9% tax on all revenue related to medical devices • Volatility associated with the election • Potential for investor backlash in lead up to 2013
Investment Information ~$600 gain 1 Year Price Graph
Analyst revisions Sales estimates EPS estimates Stryker CEO Kevin Lobo: “We expect market conditions to remain challenging in Europe...”
Recalls / FDA limitations • Rejuvenate hip implant recall / potential litigation • Wingspan stint for ischemic stroke recommended by the FDA only patients with no other options
Better opportunities in healthcare • Healthcare indices have rallied this year, with only modest gains by SYK • Starting in 2013, the Affordable Care Act mandates a 2.9% tax on all revenue related to medical devices • Volatility associated with the election • Potential for investor backlash in lead up to 2013
Management shuffle • Kevin Lobo named CEO on Oct. 1 • Currently no CFO, but former CFO Dean Bergy remains an advisor • Potential difficulties transitioning to new management
Stryker manufactures medical technologies. • Original thesis: Stryker is a leading medical technology manufacturer with potential for expansion • Rationale for sale • Management shuffle • Disappointing results • Recalls, FDA notices, potential litigation • Regulatory concerns make medical devices less appealing